JP2008521788A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008521788A5 JP2008521788A5 JP2007542134A JP2007542134A JP2008521788A5 JP 2008521788 A5 JP2008521788 A5 JP 2008521788A5 JP 2007542134 A JP2007542134 A JP 2007542134A JP 2007542134 A JP2007542134 A JP 2007542134A JP 2008521788 A5 JP2008521788 A5 JP 2008521788A5
- Authority
- JP
- Japan
- Prior art keywords
- dispersant
- active ingredient
- pharmaceutically active
- particles
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002270 dispersing agent Substances 0.000 claims 45
- 239000004480 active ingredient Substances 0.000 claims 39
- 239000002245 particle Substances 0.000 claims 32
- 238000000034 method Methods 0.000 claims 28
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 15
- 238000009472 formulation Methods 0.000 claims 10
- 239000003380 propellant Substances 0.000 claims 8
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims 7
- 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 claims 7
- 239000007787 solid Substances 0.000 claims 7
- 239000011246 composite particle Substances 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 239000006184 cosolvent Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000011248 coating agent Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Chemical class 0.000 claims 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 1
- 102000004257 Potassium Channel Human genes 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 239000000150 Sympathomimetic Substances 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 239000000674 adrenergic antagonist Substances 0.000 claims 1
- 210000002934 adrenergic neuron Anatomy 0.000 claims 1
- 239000002160 alpha blocker Substances 0.000 claims 1
- 150000003862 amino acid derivatives Chemical class 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000001022 anti-muscarinic effect Effects 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127090 anticoagulant agent Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 229940082988 antihypertensives serotonin antagonists Drugs 0.000 claims 1
- 239000003420 antiserotonin agent Substances 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 150000001557 benzodiazepines Chemical class 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 230000000994 depressogenic effect Effects 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 229940125697 hormonal agent Drugs 0.000 claims 1
- 239000003668 hormone analog Substances 0.000 claims 1
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
- 239000003149 muscarinic antagonist Substances 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- 150000002823 nitrates Chemical class 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 108020001213 potassium channel Proteins 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- 150000003873 salicylate salts Chemical class 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 239000000952 serotonin receptor agonist Substances 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- -1 sulfonylureas Chemical class 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 230000001975 sympathomimetic effect Effects 0.000 claims 1
- 229940064707 sympathomimetics Drugs 0.000 claims 1
- 150000001467 thiazolidinediones Chemical class 0.000 claims 1
- 229940075420 xanthine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0426301.8A GB0426301D0 (en) | 2004-11-30 | 2004-11-30 | Pharmaceutical formulations |
| GB0426301.8 | 2004-11-30 | ||
| PCT/GB2005/050220 WO2006059152A2 (en) | 2004-11-30 | 2005-11-30 | Pharmaceutical formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008521788A JP2008521788A (ja) | 2008-06-26 |
| JP2008521788A5 true JP2008521788A5 (https=) | 2009-01-29 |
| JP5317319B2 JP5317319B2 (ja) | 2013-10-16 |
Family
ID=33561610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007542134A Expired - Fee Related JP5317319B2 (ja) | 2004-11-30 | 2005-11-30 | 医薬製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080220078A1 (https=) |
| EP (1) | EP1817015A2 (https=) |
| JP (1) | JP5317319B2 (https=) |
| CN (1) | CN101083979A (https=) |
| CA (1) | CA2589453C (https=) |
| GB (1) | GB0426301D0 (https=) |
| WO (1) | WO2006059152A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2474199T3 (es) * | 2000-11-30 | 2014-07-08 | Vectura Limited | Composiciones farmacéuticas para inhalaci�n |
| GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| US20160331729A9 (en) * | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| EP3053440B1 (en) * | 2007-04-11 | 2020-08-12 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| GB0712316D0 (en) * | 2007-06-26 | 2007-08-01 | Entripneur Ltd | A novel powder and its method of manufacture |
| GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
| GB0801876D0 (en) * | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| US20130160761A1 (en) * | 2008-11-04 | 2013-06-27 | Cipla Limited | Pharmaceutical Aerosol Composition |
| WO2010086872A1 (en) | 2009-01-29 | 2010-08-05 | Director General, Defence Research & Development Organisation | A wool care composition |
| PL3111927T3 (pl) * | 2009-05-29 | 2020-06-29 | Pearl Therapeutics, Inc. | Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| GB0910375D0 (en) * | 2009-06-16 | 2009-07-29 | Biocopea Ltd | Drug composition and its use in therapy |
| US10016437B2 (en) | 2009-06-16 | 2018-07-10 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| US9308211B2 (en) | 2009-06-16 | 2016-04-12 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| US9314465B2 (en) | 2009-06-16 | 2016-04-19 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| DE102009049470A1 (de) * | 2009-10-15 | 2011-04-28 | Süd-Chemie AG | Verfahren zur Herstellung von feinteiligen Lithiumtitan-Spinellen und deren Verwendung |
| US9248110B2 (en) | 2010-03-18 | 2016-02-02 | Steven Lehrer | Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis |
| WO2011115988A1 (en) * | 2010-03-18 | 2011-09-22 | Steven Lehrer | Compositions and methods of treating and preventing lung cancer |
| CN104257610A (zh) * | 2010-04-01 | 2015-01-07 | 奇斯药制品公司 | 用于制备可吸入干粉所用的载体颗粒的方法 |
| CN102309456B (zh) * | 2010-07-02 | 2013-05-01 | 北京化工大学 | 一种厄贝沙坦纳微复合粉体与片剂及其制备方法 |
| CN102836125A (zh) * | 2011-06-23 | 2012-12-26 | 王晓青 | 治疗低血容量休克的丙戊酸及其盐的鼻腔给药制剂 |
| TWI597072B (zh) | 2011-10-11 | 2017-09-01 | 吉斯藥品公司 | 包覆脂肪酸的β－致效劑之結晶微粒 |
| WO2014145699A1 (en) * | 2013-03-15 | 2014-09-18 | New Jersey Institute Of Technology | System and method for fabrication of uniform polymer films containing nano and micro particles via continuous drying process |
| SG11201507286QA (en) | 2013-03-15 | 2015-10-29 | Pearl Therapeutics Inc | Methods and systems for conditioning of particulate crystalline materials |
| CN104274426A (zh) * | 2013-07-03 | 2015-01-14 | 陆克塞纳医药公司 | 昂丹司琼细粉、昂丹司琼气溶胶组合物及其用途 |
| CN117695207A (zh) * | 2015-12-24 | 2024-03-15 | 菲利普莫里斯生产公司 | 带香味尼古丁粉末 |
| CN107550919A (zh) * | 2017-09-04 | 2018-01-09 | 杭州旦承医药科技有限公司 | 唑来膦酸的用途及粉雾剂和制备方法 |
| CN107441101A (zh) * | 2017-09-04 | 2017-12-08 | 杭州旦承医药科技有限公司 | 伊班膦酸钠的用途及粉雾剂和制备方法 |
| JP7493449B2 (ja) * | 2017-09-22 | 2024-05-31 | ヴェクチュラ インコーポレイテッド | ステアリン酸マグネシウムを含む乾燥粉末組成物 |
| US10786456B2 (en) * | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| GB201912686D0 (en) * | 2019-09-04 | 2019-10-16 | Reown Pharma Inc | Pharmaceutical composition |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2077229B (en) * | 1980-05-16 | 1983-08-03 | Neotechnic Eng Ltd | Valve assembly for a pressurized aerosoldispensing container |
| US4819834A (en) * | 1986-09-09 | 1989-04-11 | Minnesota Mining And Manufacturing Company | Apparatus and methods for delivering a predetermined amount of a pressurized fluid |
| GB9515182D0 (en) * | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
| US6423298B2 (en) * | 1998-06-18 | 2002-07-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical formulations for aerosols with two or more active substances |
| US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| GB9827145D0 (en) * | 1998-12-09 | 1999-02-03 | Co Ordinated Drug Dev | Improvements in or relating to powders |
| GB0008411D0 (en) * | 2000-04-05 | 2000-05-24 | Vectura Ltd | Pharmaceutical preparations and their manufacture |
| GB0009469D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
| GB0009468D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
| PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0010709D0 (en) * | 2000-05-03 | 2000-06-28 | Vectura Ltd | Powders for use a in dry powder inhaler |
| JP5698423B2 (ja) * | 2000-06-27 | 2015-04-08 | ベクトゥラ・リミテッド | 医薬組成物で使用するための粒子の製造法 |
| WO2002043702A2 (en) * | 2000-11-30 | 2002-06-06 | Vectura Limited | Pharmaceutical compositions for inhalation |
| ES2474199T3 (es) * | 2000-11-30 | 2014-07-08 | Vectura Limited | Composiciones farmacéuticas para inhalaci�n |
| US20040052733A1 (en) * | 2000-11-30 | 2004-03-18 | Staniforth John Nicholas | Pharmaceutical compositions for inhalation |
| DE60140268D1 (de) * | 2000-11-30 | 2009-12-03 | Vectura Ltd | Partikel zur verwendung in einer pharmazeutischen zusammensetzung |
| PT1372608E (pt) * | 2001-03-30 | 2008-01-04 | Jagotec Ag | Formulações de aerossol médicas |
| GB0109384D0 (en) * | 2001-04-12 | 2001-05-30 | Vectura Ltd | Pharmaceutical products, preparation and uses thereof |
| WO2003020241A2 (en) * | 2001-09-05 | 2003-03-13 | Vectura Limited | Functional powders for oral delivery |
| WO2003074029A1 (en) * | 2002-03-07 | 2003-09-12 | Vectura Limited | Fast melt multiparticulate formulations for oral delivery |
| WO2004032901A1 (en) * | 2002-10-11 | 2004-04-22 | Vectura Limited | Pharmaceutical excipients comprising inorganic particles in association with an organic polymeric material and forming a solid reticulated matrix, compositions, manufacturing and use thereof |
| CA2522231A1 (en) * | 2003-04-14 | 2004-10-21 | Vectura Ltd | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation |
| JP2006522634A (ja) * | 2003-04-14 | 2006-10-05 | ベクトゥラ・リミテッド | 投与効率を向上させるデバイス及び製薬組成 |
| US20060147389A1 (en) * | 2004-04-14 | 2006-07-06 | Vectura Ltd. | Devices and pharmaceutical compositions for enhancing dosing efficiency |
| EP1663164A2 (en) * | 2003-09-15 | 2006-06-07 | Vectura Limited | Methods for preparing pharmaceutical compositions |
| GB0321607D0 (en) * | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
-
2004
- 2004-11-30 GB GBGB0426301.8A patent/GB0426301D0/en not_active Ceased
-
2005
- 2005-11-30 US US11/791,670 patent/US20080220078A1/en not_active Abandoned
- 2005-11-30 EP EP05813625A patent/EP1817015A2/en not_active Withdrawn
- 2005-11-30 CA CA2589453A patent/CA2589453C/en not_active Expired - Fee Related
- 2005-11-30 JP JP2007542134A patent/JP5317319B2/ja not_active Expired - Fee Related
- 2005-11-30 CN CNA2005800410147A patent/CN101083979A/zh active Pending
- 2005-11-30 WO PCT/GB2005/050220 patent/WO2006059152A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008521788A5 (https=) | ||
| AU2006212021B2 (en) | Pharmaceutical compositions useful in the transmucosal administration of drugs | |
| AU754379B2 (en) | Therapies for treating pulmonary diseases | |
| WO2004026262A3 (en) | Abuse-resistant pharmaceutical compositions | |
| JP4523153B2 (ja) | 易溶性薬物の二層性放出制御送達システムおよび方法 | |
| KR101568100B1 (ko) | 오피오이드 진통제를 포함하는 변질 변조 방지 경구용 제약 제형 | |
| AU634529B2 (en) | Controlled release delivery device for macromolecular proteins | |
| WO2006059152A3 (en) | Pharmaceutical formulations | |
| CN105246458A (zh) | 用于治疗剂递送的微阵列及其使用方法 | |
| WO2004064815A8 (en) | Oral dosage formulation | |
| EP0222411B1 (en) | Method of preparing sustained-release pharmaceutical preparation | |
| JP2004515455A5 (https=) | ||
| CA2391923A1 (en) | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions | |
| EP1356808A3 (en) | Coating technique for deposition of drug substance on a substrate | |
| US20100112054A1 (en) | Tablets and discs with compartments with two or more drugs for release at certain intervals and with specific rates | |
| WO2007103557A3 (en) | Coating capsules with active pharmaceutical ingredients | |
| JP2018504454A (ja) | 積層徐放型マイクロビーズ及びその作製方法 | |
| WO2005053638A3 (en) | Composition and delivery system | |
| CZ20033435A3 (cs) | Přípravek obsahující inhibitor PDE@ a antagonistu H�@receptoru a jeho použití pro výrobu léčiva pro léčbu respiračních onemocnění | |
| Demiri et al. | Gluing Pills Technology: A novel route to multilayer tablet manufacturing | |
| US5328697A (en) | Compositions and processes for the sustained release of drugs | |
| NZ504566A (en) | The amorphous form of zafirulkast (Form A), a leukotriene antagonist, as a pharmaceutical composition in a multi-layered sustained release formulation for treatment of asthma and related conditions | |
| US20040091533A1 (en) | Antihistamine and decongestant system | |
| RU2024128483A (ru) | Минимизация агломерации покрывающего материала частиц лекарственного средства при хранении для стабилизации времени распада фармацевтических продуктов | |
| WO2007138557A3 (en) | Controlled-release multiple unit pharmaceutical compositions |